Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124976 | 0.83 | POLB (0.41) | POLBLMNAKDM4EADORA2ASYK | |
| SCHEMBL28083263 | 0.81 | TDP1 (0.40) | POLBLMNAKDM4EADORA2APDPK1 | |
| SCHEMBL20303135 | 0.80 | ALDH1A1 (0.41) | POLBKDM4EPKMALDH1A1HPGD | |
| SCHEMBL25950177 | 0.79 | PLAU (0.44) | POLBLMNAKDM4EADORA2AADORA2B | |
| SCHEMBL7718725 | 0.76 | KDM4E (0.44) | POLBLMNAKDM4EADORA2AADORA3 | |
| SCHEMBL25562756 | 0.76 | PLAU (0.37) | POLBLMNAKDM4EADORA2AADORA2B | |
| SCHEMBL282566 | 0.75 | POLB (0.35) | POLBLMNAKDM4EADORA2APDPK1 | |
| SCHEMBL20302593 | 0.75 | NPSR1 (0.52) | LMNAKDM4EPKMALDH1A1HPGD | |
| SCHEMBL29452887 | 0.75 | POLB (0.35) | POLBLMNAKDM4EADORA2APDPK1 | |
| SCHEMBL28275637 | 0.74 | KDM4E (0.42) | POLBLMNAKDM4EADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-118829631-A | Pyrazine compounds as FLT3 inhibitors | 拜欧米富士恩公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023027966-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | POLB 1489/4885LMNA 3786/4885KDM4E 2175/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | POLB 1379/4885LMNA 3708/4885KDM4E 2617/4885 |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | FLT3, MCL1, JAK2 | POLB 1028/4885LMNA 3632/4885KDM4E 2031/4885 |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | POLB 1489/4885LMNA 3786/4885KDM4E 2175/4885 |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | FLT3, MEN1, FEM1B | POLB 666/4885LMNA 953/4885KDM4E 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.